Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease

View Full Paper
Ask AI
Bookmark
Share

Authors

WYWenyu Yang

Discussion

Loading...

Member takes

Overview

Clinical trial demonstrates 76.9% response rate in pediatric patients with steroid-refractory chronic graft-versus-host disease, indicating treatment efficacy and tolerability.

Key Points

  • To investigate the efficacy and safety of belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease.
  • 13 pediatric patients with SR-cGVHD were included
  • All patients received belumosudil
  • Endpoints included overall response rate, failure-free survival, overall survival, and adverse effects documented.
  • Overall response rate was 76.9%
  • Failure-free survival and overall survival were 68.6% and 100% respectively
  • Adverse effect rates were comparable to the control group.

Cite This Study

Wenyu Yang (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd07https://doi.org/10.1182/blood-2025-7834
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety2025
  2. 2Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study2026
  3. 3Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft‐Versus‐Host Disease: A Systematic Review and Meta‐Analysis2026
  4. 4Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US2025
  5. 5FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy2022 · 58 citations